Niagen Bioscience, Inc.

Name: Niagen Bioscience, Inc. standardized financial statements, quarterly
Creator: Listed

NAGENasdaqCIK 1386570HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$29.8m, Q2 FY2026

Operating income$700.0k, Q2 FY2026

Net income$963.0k, Q2 FY2026

Niagen Bioscience, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$m	19.5	21.2	22.2	22.7	25.6	29.1	30.5	31.1	34.0	33.8	31.5	29.8
Cost of revenue	$m	7.5	8.3	8.7	9.0	9.3	10.9	11.2	10.9	12.1	12.1	11.5	10.5
Gross profit	$m	12.0	12.9	13.5	13.7	16.2	18.2	19.3	20.2	21.9	21.7	20.0	19.3
Research and development	$m	1.2	1.2	2.1	1.3	1.3	1.3	1.3	1.6	1.8	1.7	1.5	1.5
Operating income	$m	(1.1)	(0.2)	(0.7)	(0.3)	1.6	7.1	4.8	3.2	4.2	4.1	1.6	0.7
Interest expense	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Income tax	$m	not reported	not reported	0.0	0.0	0.0	0.3	0.2	0.1	0.2	0.3	0.4	0.1
Net income	$m	(1.0)	0.1	(0.5)	(0.0)	1.9	7.2	5.1	3.6	4.6	4.1	6.3	1.0
Diluted EPS	$ per share	(0.01)	not reported	(0.01)	0.00	0.02	not reported	0.06	0.04	0.05	not reported	0.07	0.01
Basic EPS	$ per share	(0.01)	not reported	(0.01)	0.00	0.02	not reported	0.07	0.05	0.06	not reported	0.08	0.01

Balance sheet

Cash and equivalents$64.1m, Q3 FY2025

Shareholders' equity$82.5m, Q2 FY2026

Niagen Bioscience, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	26.6	27.2	27.4	27.7	32.2	44.5	55.5	60.3	64.1	not reported	not reported	not reported
Current assets	$m	47.2	49.5	49.0	49.3	52.1	64.1	76.2	86.7	93.6	96.8	105	97.8
Total assets	$m	53.5	55.0	54.1	54.0	56.5	68.3	81.3	91.5	98.1	106	114	107
Current liabilities	$m	19.4	20.6	19.5	17.9	17.7	17.9	20.8	22.3	22.7	19.9	22.8	15.1
Total liabilities	$m	26.2	26.5	25.1	23.3	22.2	22.2	26.0	27.3	27.5	29.9	32.0	24.1
Long-term debt	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Current portion of debt	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Shareholders' equity	$m	27.3	28.5	29.0	30.7	34.4	46.1	55.3	64.2	70.7	76.5	82.3	82.5

Cash flow

Operating cash flow$2.8m, Q2 FY2026

Share repurchases$2.8m, Q2 FY2026

Niagen Bioscience, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$k	396	649	295	(264)	3,495	8,583	7,883	1,250	3,692	679	(1,194)	2,772
Capital expenditure	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Share repurchases	$k	not reported	not reported	not reported	not reported	not reported	not reported	0.0	0.0	not reported	not reported	2,354	2,767

Diluted shares (weighted)82.50m, Q2 FY2026

Niagen Bioscience, Inc., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	68.3	74.8	75.0	75.1	75.2	75.6	77.8	83.2	86.2	86.6	84.6	82.5

Shares outstanding: 79.13m at Jul 30, 2026, from the cover of the 10-Q filed Aug 4, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:38 ET. Listed shows no prices and gives no investment advice.